NCT05032235View on ClinicalTrials.gov

Safety and Pharmacokinetics of Fluzoparib in Healthy Subjects and Those With Impaired Kidney Function

PHASE1CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

November 9, 2021

Primary Completion Date

December 4, 2023

Study Completion Date

December 5, 2023

Conditions
Renal Impairment
Interventions
DRUG

Fluzoparib

Normal Renal Function:A single oral dose of Fluzoparib will be administered.

DRUG

Fluzoparib

Mild Renal Impairment:A single oral dose of Fluzoparib will be administered.

DRUG

Fluzoparib

Moderate Renal Impairment:A single oral dose of Fluzoparib will be administered.

Trial Locations (1)

400000

The second affiliated hospital of Chongqing medical university, Chongqing

All Listed Sponsors
lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT05032235 - Safety and Pharmacokinetics of Fluzoparib in Healthy Subjects and Those With Impaired Kidney Function | Biotech Hunter | Biotech Hunter